

**IMLYGIC<sup>®</sup>**  
(talimogene laherparepvec)

# PATIENT ALERT CARD

**Please carry this card  
with you at all times.**

Present this card to healthcare  
professionals (doctor, nurse)  
upon consultation  
or hospitalisation.

This card should be folded along the dotted lines.

Patient's Name: \_\_\_\_\_

IMLYGIC<sup>®</sup> Prescriber's (Doctor's) Name: \_\_\_\_\_

Doctor's Phone Number: \_\_\_\_\_

Name of Centre/Institution (if applicable): \_\_\_\_\_

Start Date of IMLYGIC<sup>®</sup> Treatment: \_\_\_\_\_

IMLYGIC <sup>®</sup> Batch Numbers	Dates Administered
_____	_____
_____	_____
_____	_____
_____	_____
_____	_____

**Instructions to prescriber: Please review important safety information with your patients every time you administer IMLYGIC<sup>®</sup>.**

# IMLYGIC<sup>®</sup>

(talimogene laherparepvec)

## Instructions to Patients:

If you get any side effects, talk to your doctor, pharmacist or nurse.

Side effects can be reported directly to the Health Products Regulatory Authority (HPRA) using the available methods via [www.hpra.ie](http://www.hpra.ie).

By reporting side effects you can help provide more information on the safety of this medicine. Side effects should also be reported to Amgen Limited on +44 (0)1223 436441 or Freephone 1800 535 160. Always provide the batch number from your Patient Alert Card when reporting side effects.

## You can get more information from:

IMLYGIC<sup>®</sup> Package Leaflet and Patient Safety Brochure available from your doctor, online at <https://www.medicines.ie/> or via Amgen Medical Information on 1800 535 160 or at [gbinfoline@amgen.com](mailto:gbinfoline@amgen.com).

**If you or one of your close contacts develops a herpetic lesion (for example cold sore), please call your doctor (name and phone number provided on front), and advise your close contact to call their doctor.**

The herpetic lesion can be tested to determine if it is caused by IMLYGIC<sup>®</sup>. Acyclovir is an antiviral drug that may be used to treat the herpetic lesion caused by IMLYGIC<sup>®</sup>, as determined by your doctor.

## INSTRUCTIONS TO PRESCRIBER:

A new card is to be completed with the first administration of IMLYGIC<sup>®</sup>. Record the batch number for every administration of IMLYGIC<sup>®</sup> on this card. Please supply a new card to the patient if needed during treatment.

## INFORMATION FOR HEALTHCARE PROFESSIONALS:

IMLYGIC<sup>®</sup> Summary of Product Characteristics is available online at <https://www.medicines.ie/> and at <https://www.hpra.ie/>.